Bibliografía del artículo
1. B-Lajoie MR, Drouin O, Bartlett G, Nguyen Q, Low A, Gavriilidis G. Incidence and prevalence of opportunistic and other infections and the impact of antiretroviral therapy among HIV-infected children in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis 62(12):1586-94, 2016. https://doi.org/10.1093/cid/ciw139.
2. Kim JH, Psevdos G Jr, Gonzalez E, Singh S, Kilayko MC, Sharp V. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART). Infection 41(2):545-51, 2013. https://doi.org/10.1007/s15010-012-0386-7.
3. Sentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, Du P. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep 11(1):6283, 2021. https://doi.org/10.1038/s41598-021-85359-3.
4. Álvarez Barreneche MF, Restrepo Castro CA, Hidrón Botero A, Villa Franco JP, Trompa Romero IM, Restrepo Carvajal L, et al. Hospitalization causes and outcomes in HIV patients in the late antiretroviral era in Colombia. AIDS Res Ther 14:60, 2017. https://doi.org/10.1186/s12981-017-0186-3.
5. Ford N, Vitoria M, Penazzato M, Doherty M, Shubber Z, Meintjes G et al. Causes of hospital admission among people living with HIV worldwide: A systematic review and meta-analysis. The Lancet HIV 2(10):e438-e444, 2015. https://doi.org/10.1016/S2352-3018(15)00137-X.
6. Meintjes G, Kerkhoff AD, Burton R, et al. HIV-related medical admissions to a South African district hospital remain frequent despite effective antiretroviral therapy scale-up. Medicine (Baltimore) 94(50):e2269, 2015. https://doi.org/10.1097/MD.0000000000002269.
7. Ministerio de Salud Pública del Ecuador, Subsecretaría Nacional de Vigilancia de la Salud Pública. Dirección Nacional de Estrategias de Prevención y Control. Estrategia Nacional de VIH/sida-ITS. 2021, Boletín Anual de VIH/sida Ecuador 2020. [Citado 2022, abril 22] disponible en: https://www.salud.gob.ec/wp-content/uploads/2021/06/Boletin-anual-VIH-Ecuador-2020.pdf.
8. Tumbaco-Quirumbay J, Durán-Pincay Y. VIH/Sida en Ecuador: Epidemiología, comorbilidades, mutaciones y resistencia a antirretrovirales. Dom Cien 7(3):341-45, 2012. http://dx.doi.org/10.23857/dc.v7i3.1997.
9. Bosh KA, Hall HI, Eastham L, Daskalakis DC, Mermin JH. Estimated annual number of HIV infections ; United States, 1981-2019. MMWR Morb Mortal Wkly Rep 70(22):801-6, 2021. https://doi.org/10.15585/mmwr.mm7022a1.
10. Boyd AT, Oboho I, Paulin H, Ali H, Godfrey C, Date A, Sean Cavanaugh J. Addressing advanced HIV disease and mortality in global HIV programming. AIDS Res Ther 17(1):40, 2020. https://doi.org/10.1186/s12981-020-00296-x.
11. Morey León G, Bonilla R, González González M, Erazo L, Rodríguez F, Luzuriaga P. Infecciones oportunistas en pacientes con VIH/SIDA atendidos en el Hospital de Infectología, Guayaquil, Ecuador. FACSALUD-UNEMI. 4(7):37-42, 2020. http://dx.doi.org/10.29076/issn.2602-8360vol4iss7.2020pp37-42p.
12. Panel de expertos de GeSIDA y División de control de VIH, ITS, hepatitis virales y tuberculosis. Plan Nacional sobre el Sida. Documento de consenso de Gesida/plan nacional sobre el sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. Actualización 2022. [Citado 2023, enero 19] Disponible en:
https://gesida-seimc.org/wp-content/uploads/2022/01/Guias2022_Borrador.pdf.
13. World Health Organization. International statistical classification of diseases and related health problems. 10th revision. Vesión 2019. [Citado2022, abril 15] Disponible en: https://www.who.int/standards/classifications/classification-of-diseases.
14. Kusejko K, Günthard HF, Olson GS, Zens K, Darling K, Khanna N. Swiss HIV Cohort Study. Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. PLoS Biol 18(12):e3000963, 2020. https://doi.org/10.1371/journal.pbio.3000963.
15. Sanhueza-Sanzana C, Kerr L, Kendall C. Mortality from AIDS and tuberculosis-HIV coinfection in the Chilean AIDS Cohort of 2000-2017. Cad Saude Publica 37(6):e00212920, 2021. https://doi.org/10.1590/0102-311X00212920 Erratum in: Cad Saude Publica. 2021 Jul 19;37(7):eER212920.
16. Arefaine ZG, Abebe S, Bekele E, Adem A, Adama Y, H Brockmeyer N, et al. Incidence and predictors of HIV related opportunistic infections after initiation of highly active antiretroviral therapy at Ayder Referral Hospital, Mekelle, Ethiopia: A retrospective single centered cohort study. PLoS One 15(4):e0229757, 2020. https://doi.org/10.1371/journal.pone.0229757.
17. Burke RM, Henrion MYR, Mallewa J, Masamba L, Kalua T, Khundi M. Incidence of HIV-positive admission and inpatient mortality in Malawi (2012-2019). AIDS 35(13):2191-9, 2021. https://doi.org/10.1097/QAD.0000000000003006.
18. Lewden C, Drabo YJ, Zannou DM, Maiga MY, Minta DK, Sow PS, et al. IeDEA West Africa Collaboration. Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: a multicountry survey in the antiretroviral treatment era. J Int Aids Soc 17(1):18797, 2014. https://doi.org/10.7448/IAS.17.1.18797.
19. Iroezindu MO. Disparities in the magnitude of human immunodeficiency virus-related opportunistic infections between high and low/middle-income countries: Is highly active antiretroviral therapy changing the trend? Ann Med Health Sci Res 6:4-18, 2016. http://dx.doi.org/10.4103/2141-9248.180234.
20. Rubaihayo J, Tumwesigye NM, Konde-Lule J, Wamani H, Nakku-Joloba E, Makumbi F. Frequency and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda. BMC Res Notes 9(1):501, 2016. https://doi.org/10.1186/s13104-016-2317-7.
21. Dang LVP, Nguyen QH, Ishizaki A, Larsson M, Vu NTP, Do Duy C. Prevalence of opportunistic infections and associated factors in hiv-infected men who have sex with men on antiretroviral therapy in Bach Mai hospital, Hanoi, Vietnam: a case-control study. Am J Mens Health 14(3):1557988320926743, 2020. https://doi.org/10.1177/1557988320926743.
22. Castillo M, Saúl-García Y, Hernandez-Valles R, Semprún-Hernández N, Martínez-Méndez, D. Fluconazole and voriconazole susceptibility in oral colonization isolates of Candida spp. in HIV patients. Investigación clínica. 60:275-82, 2019. https://doi.org/10.22209/IC.v60n4a02.
23. Rein SM, Lampe FC, Chaloner C et al. Causes of hospitalisation among a cohort of people with HIV from a London centre followed from 2011 to 2018. BMC Infect Dis 21:395, 2020. https://doi.org/10.1186/s12879-021-06082-y.
24. Morey León J, Mendoza R, Bajaila G, Soriano O, Escobar K. Morbilidad en pacientes infectados por VIH/SIDA en una unidad de cuidados intensivos. Revista Científica y Tecnológica UPSE 9(1):18-24, 2022. http://dx.doi.org/10.26423/rctu.v9i1.662.